Wikipedia -WSS

Wikipedia

author：focus 2025-09-27 19:49:43 - browse：1

Adam's take main illustration — Molly Ferguson/STAT

Anavex Life Sciences is in a tough spot. The serial dissembler of clinical trial results might be forced, finally, to tell the truth when it reads out its next study in Rett syndrome.

What sets Anavex apart from all the other biotechs on my radar screen is its habit of shifting the goalposts on clinical trials. Twice last year, first in February and then in December, Anavex announced “positive” outcomes from studies of its drug called blarcamesine — except the results were derived from efficacy endpoints that were not part of the original study designs.

If blarcamesine fails to achieve the pre-determined goals of clinical trials, the thinking apparently goes, then just make a post-hoc change to the study goals.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Novavax promises a turnaround & Lilly roils the obesity market
Next article： Meta's Zuckerberg and Chan on track to put $50 billion into science

hotspot

WSS

Medicare isn't yet testing food as medicine

FDA approves Eli Lilly ulcerative colitis treatment Omvoh

Physician subsidies by hospitals soar in wake of No Surprises Act

Virtual repurposing can help discover new uses for existing drugs

Children’s Hospital revives plan for pedestrian bridge

Cassava reveals details — and problems — with Alzheimer's study

Wikipedia

Wikipedia

knowledge

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Neuroscience renaissance leads to new crop of psychiatric drugs

Medical records are filled with copy

Pfizer is about to make a big push in cancer. Will investors listen?

BioMarin wins approval for gene therapy to treat hemophilia A

Laying a path for careers in science

Activists slam private health insurers over coverage restrictions

Physician subsidies by hospitals soar in wake of No Surprises Act

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

Readout Newsletter: The latest on Amylyx, Moderna, Novavax

explore

An exit interview with Bristol Myers Squibb CEO Giovanni Caforio

Covid overtakes 1918 Spanish flu as deadliest disease in U.S. history

Readout Newsletter: The latest from Bristol, Sarepta, and Novartis

Paying for Covid pills will soon shift to insurers

Readout Newsletter: XBI biotech index, Akero Therapeutics

Elisabeth Bik tackles the widespread issue of research misconduct

hotspot

hotspot

entertainment

entertainment